Clinical Scorecard: Cortisol Secretion's Impact on Pheochromocytomas and Paragangliomas: Clinical and Perioperative Considerations

At a Glance

Key Highlights

• Approximately 24.5% of patients with PPGLs exhibit autonomous cortisol secretion post-DST (>1.8 µg/dL).
• Autonomous cortisol secretion associates with older age, female predominance, larger tumor size, higher diabetes prevalence, and increased cardiovascular disease.
• Patients with autonomous cortisol secretion have higher perioperative complications including blood loss, conversion to open surgery, and prolonged hospital stay.

Guideline-Based Recommendations

Diagnosis

• Screen for autonomous cortisol secretion in PPGL patients using the 1-mg dexamethasone suppression test (DST).
• Confirm PPGL diagnosis histopathologically after surgery.
• Measure urinary and plasma metanephrines to assess catecholamine excess.

Management

• Consider routine DST screening preoperatively to identify MACS in PPGL patients.
• Optimize perioperative care anticipating higher complication risks in patients with autonomous cortisol secretion.
• Discontinue oral contraceptives at least 2 months before hormonal testing in reproductive-age women.

Monitoring & Follow-up

• Monitor glucose metabolism closely due to increased diabetes prevalence in MACS patients.
• Assess cardiovascular status given higher cardiovascular disease incidence in patients with autonomous cortisol secretion.
• Follow-up post-surgery for metabolic and cardiovascular outcomes.

Risks

• Increased perioperative complications including blood loss and need for conversion to open surgery.
• Higher prevalence of diabetes before and after surgery.
• Greater cardiovascular disease burden.

Patient & Prescribing Data

Patients with PPGLs undergoing adrenalectomy or extra-adrenal surgery

Patients with autonomous cortisol secretion require tailored perioperative management due to increased metabolic and cardiovascular risks and higher complication rates.

Clinical Best Practices

• Implement routine 1-mg DST screening for cortisol secretion in all PPGL patients preoperatively.
• Use biochemical and imaging data to stratify perioperative risk and guide surgical planning.
• Manage comorbid diabetes and cardiovascular disease aggressively in patients with MACS.
• Avoid confounding medications such as oral contraceptives and CYP3A4 modulators before hormonal testing.

References

• European Society of Endocrinology Clinical Practice Guideline on Diagnosis and Treatment of MACS